Efficacy, Safety, and Tolerability Study of Apremilast to Treat Early Oligoarticular Psoriatic Arthritis.
Status:
Recruiting
Trial end date:
2023-08-07
Target enrollment:
Participant gender:
Summary
This clinical study will test the effects of a drug called apremilast in oligoarticular
psoriatic arthritis with less than 5 years of disease duration. In previous studies,
apremilast has been shown to be safe and efficacious in reducing signs and symptoms of
psoriatic arthritis, as well as improving physical function. This study will compare the
effects of apremilast to placebo on psoriatic arthritis subjects in which the number of
affected joints is limited (greater than 1 but less or equal to 4). About 285 patients
worldwide will take part in this study.